(Reuters) - AstraZeneca said on Friday its drug for preventing infant RSV, Beyfortus (nirsevimab), was recommended for approval in the European Union by a European Medicines Agency committee.
The drugmaker also said if Beyfortus is approved, it would become the first protective option for newborn and infant population against RSV lower respiratory tract disease.